Loading
Life sciences · Journal article
Journal of Medical Imaging and Radiation Oncology · September 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Introduction In recent years, cervical cancer incidence has been on the decline in Australia, likely due to the HPV vaccination and an improved screening programme. However, an estimated 900 new cases will be diagnosed in 2025. The standard of care for locally advanced cervical cancer (LACC) is chemoradiotherapy, comprising external beam radiation therapy with concurrent cisplatin followed by image guided brachytherapy (IGBT), which is essential for optimal local control. Some patients will be ineligible for IGBT due to comorbidities, anaesthetic risk or technical challenges, with alternative EBRT boost techniques demonstrating higher toxicity and poorer patient outcomes. MR‐guided stereotactic body radiotherapy (MRg‐SBRT) offers improved soft tissue visualisation and daily adaptive planning, enabling accurate target coverage and reduced dose to organs at risk. MRg‐SBRT is an investigational non‐invasive boost option with emerging evidence supporting feasibility Methods We describe our early experience treating four patients with cervical cancer who were ineligible for IGBT following pelvic EBRT ± chemotherapy. All patients completed treatment with adaptive MRg‐SBRT. Results Median high‐risk clinical target volume (HR‐CTV) D98% was 78.7 Gy EQD2 10, demonstrating adequate target coverage. Early imaging showed one complete response, one local progression and one combined local and metastatic progression. Acute toxicities were predominantly Grade 1, with one case of Grade 3 pelvic pain and no Grade 4 events. Conclusions MRg‐SBRT boost was feasible and well tolerated, achieving reasonable dose escalation with acceptable toxicity, representing a potential alternative for patients' ineligible for brachytherapy. Trial Registration MARGARITA Protocol, NCT05937958